ClinicalTrials.gg
CompletedNCT00666263Updated May 19, 2021Results posted

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

A Phase 3 interventional study of Immune Globulin Intravenous (human), 10% and 0.25% human albumin solution (Placebo) in Multifocal Motor Neuropathy, sponsored by Baxalta now part of Shire. Completed at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the efficacy (effect on grip strength and disability) and safety/tolerability of IGIV, 10% in subjects with Multifocal Motor Neuropathy.

02

Conditions studied

  • Multifocal Motor Neuropathy
03

In context

Lead sponsor

Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Baxalta became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from the participant prior to any study-related procedures and study product administration
  • Diagnosis of definite or probable MMN based on the criteria of the American Association of Electrodiagnostic Medicine (AAEM) (Olney et al., 2003, see Section 15.1 for the full length publication). Conduction block can be identified by a drop in amplitude. Diagnosis can be based on chart records a) Hand grip (finger flexor) weakness of Medical Research Council (MRC) grade 4 or less at disease onset or appearing prior to screening; b) No upper motor signs c) No bulbar or cranial signs or symptoms; d) No clinically identifiable sensory abnormalities
  • Must be on a stable regimen of IGIV for at least 3 months prior to first study product administration
  • Treatment interval with IGIV of 2 to 5 weeks (+/- 3 days)
  • Dose of IGIV to be 0.4 to 2.0 g per kg BW and infusion cycle
  • Participants are adults, male or female, at least 18 years of age
  • If female and capable of bearing children - have a negative urine pregnancy test result at enrollment and agree to employ adequate measures for the duration of the study
  • Ability and willingness to travel to the study site for infusions and assessments if required by the protocol

Exclusion criteria

Exclusion Criteria:

  • Any clinical or electrophysiological evidence of coexisting neuropathy which may interfere with outcome assessments, such as diabetic neuropathy, toxic neuropathy, or neuropathy due to systemic lupus erythematosus
  • Treatment with other agents besides IGIV, which has demonstrated efficacy in MMN such as cyclophosphamide during the 3 months prior to enrollment (or treatment with Rituximab during the 12 months prior to enrollment). Pre-study treatment with mycophenolate mofetil or azathioprine is permitted if the dose has been stable for 3 months prior to enrollment.
  • Cerebrospinal fluid protein > 100 mg/dL (if done as part of a previous evaluation)
  • Participants positive at enrollment for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for (HCV), PCR for (HIV) Type 1
  • Participants with levels of (ALT) or aspartate aminotransferase (AST) > 2.5 times the for the testing laboratory
  • Participants with neutropenia (defined as an [ANC]≤1000/mm\^3)
  • Participants with serum creatinine levels greater than 1.5 times the upper limit of normal for age and gender
  • Participants with other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Participants with a history of thrombotic episodes (deep vein thrombosis, myocardial infarction, cerebrovascular accident)
  • Participants who received any blood or blood product exposure other than an IGIV, subcutaneous immunoglobulin, immune serum globulin (ISG) preparation, or albumin within the 6 months prior to enrollment
  • Participants with an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV or human albumin
  • Participants with immunoglobulin A (IgA) deficiency and known anti IgA antibodies
  • Participants using another product or device within 30 days prior to enrollment
  • Participants who are unable or unwilling to meet all the requirements of this study
  • If female, is pregnant or lactating at time of enrollment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    IGIV, 10% Then Placebo

    STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3). Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle).

    Biological: Immune Globulin Intravenous (human), 10% · Biological: 0.25% human albumin solution (Placebo)

  • Experimental
    Placebo Then IGIV, 10%

    STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3). Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)

    Biological: Immune Globulin Intravenous (human), 10% · Biological: 0.25% human albumin solution (Placebo)

Interventions

  • Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)

    Also known as: IGIV, 10%, GAMMAGARD LIQUID, KIOVIG

  • Biological0.25% human albumin solution (Placebo)

    Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1

    Also known as: BUMINATE 25%, Albumin (Human) Solution, Human Albumin 200 g/L Baxter

06

What researchers measure

Primary outcomes

  1. Grip Strength in the More Affected Hand

    The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  2. Mean Relative Change in Grip Strength in the More Affected Hand

    Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  3. Co-Primary Endpoint: Guy's Neurologic Disability Scale (GNDS) for Upper Limbs

    GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  4. Co-Primary Endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS)

    GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  5. Rate of Temporally Associated Adverse Events (AEs) Per Infusion

    The total number of all AEs which begin during or within 72 hours of completion of an infusion, irrespective of being related or not related to the study product (IGIV, 10% or Placebo), divided by the total number of infusions, and multiplied by 100.

    Time frame: Within 72 hours of completion of an infusion during the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  6. The Percentage of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  7. The Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  8. The Percentage of Participants Reporting One or More Moderate or Severe AEs That Began During Infusion or Within 72 Hours of Completion of an Infusion

    Time frame: Within 72 hours of completion of an infusion during the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

Secondary outcomes

  1. Percentage of Participants With at Least a 30% Decline in Relative Grip Strength in the More Affected Hand (Measured Using a DynEx Digital Dynamometer)

    Relative grip strength change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  2. Grip Strength in the Less Affected Hand

    The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  3. Mean Relative Change in Grip Strength in the Less Affected Hand

    Relative Change is defined as 100 \* (End of the Cross-Over Period - Baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  4. Proportion of Participants That Were Accelerated Forward Into the Next Stabilization Phase (ie Switched to Open-Label IGIV, 10%)

    Participants were permitted to switch from blinded treatment with placebo or IGIV, 10% to open label IGIV, 10% if they and investigator agreed that deterioration had occurred to the extent that the participant had unacceptable difficulty carrying out daily activities involving the affected muscles, or decline in grip strength of ≥50% in the more affected hand had occurred.

    Time frame: During the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  5. Patient Global Impression of Change

    Patient Global Impression of Change was measured on an ordinal scale of 1-7, higher scores representing greater perceived deterioration since the previous efficacy assessment (ranging from (1) very much improved to very much worse (7)). 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

    Time frame: Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  6. Overall Disability Sum Score

    The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability).

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  7. Overall Disability Sum Score - Standardized

    The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  8. Mean Relative Change in Overall Disability Sum Score

    Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability (from 0, "no signs of disability" to 12, "most severe disability"). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  9. Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand

    The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  10. Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand

    Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  11. Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand

    The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  12. Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand

    Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  13. Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)

    The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".

    Time frame: Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit

  14. Mean Relative Change in Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)

    Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".

    Time frame: Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)

  15. Rate of Related AEs Per Infusion

    The total number of AEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  16. Rate of Related SAEs Per Infusion

    The total number of SAEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  17. The Proportion of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  18. The Proportion of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

  19. The Proportion of Infusions Associated With One or More AEs Related to the Study Product

    Time frame: Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)

07

Results

Posted Mar 13, 2013

Participant flow

Recruitment was conducted in the U.S., Canada, and Europe at 17 study sites. The first participant was enrolled in August 2008.

Study Part 1 (Stabilization Phase 1)
Participant flow — Study Part 1 (Stabilization Phase 1)
MilestoneIGIV, 10% Then Placebo (During Cross-Over Periods)Placebo Then IGIV, 10% (During Cross-Over Periods)
Started2222
Completed2221
Not completed01
Withdrew: Adverse event01
Study Part 2 (Cross-over Period 1)
Participant flow — Study Part 2 (Cross-over Period 1)
MilestoneIGIV, 10% Then Placebo (During Cross-Over Periods)Placebo Then IGIV, 10% (During Cross-Over Periods)
Started2221
Completed2221
Not completed00
Study Part 3 (Stabilization Phase 2)
Participant flow — Study Part 3 (Stabilization Phase 2)
MilestoneIGIV, 10% Then Placebo (During Cross-Over Periods)Placebo Then IGIV, 10% (During Cross-Over Periods)
Started2221
Completed2221
Not completed00
Study Part 4 (Cross-over Period 2)
Participant flow — Study Part 4 (Cross-over Period 2)
MilestoneIGIV, 10% Then Placebo (During Cross-Over Periods)Placebo Then IGIV, 10% (During Cross-Over Periods)
Started2221
Completed2121
Not completed10
Withdrew: Adverse event10
Study Part 5 (Stabilization Phase 3)
Participant flow — Study Part 5 (Stabilization Phase 3)
MilestoneIGIV, 10% Then Placebo (During Cross-Over Periods)Placebo Then IGIV, 10% (During Cross-Over Periods)
Started2121
Completed2120
Not completed01
Withdrew: Withdrawal by subject01
End of Study Visit
Participant flow — End of Study Visit
MilestoneIGIV, 10% Then Placebo (During Cross-Over Periods)Placebo Then IGIV, 10% (During Cross-Over Periods)
Started2222
Completed2222
Not completed00

Outcome measures

PrimaryGrip Strength in the More Affected Hand

The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · kilograms
Grip Strength in the More Affected Hand
kilogramsBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)18.14 (9.30 to 30.43)21.68 (14.05 to 30.83)19.54 (10.15 to 29.15)19.39 (12.75 to 33.25)11.28 (5.50 to 25.92)17.77 (9.23 to 27.07)17.37 (10.80 to 29.03)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)13.17 (5.30 to 20.08)14.17 (8.08 to 27.47)8.38 (4.86 to 17.03)14.18 (7.60 to 27.35)15.98 (10.73 to 29.65)14.28 (9.47 to 28.25)14.00 (7.48 to 24.82)
PrimaryMean Relative Change in Grip Strength in the More Affected Hand

Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Mean · Percent change in grip strength
Mean Relative Change in Grip Strength in the More Affected Hand
Percent change in grip strengthArm 1: IGIV, 10% Then Placebo- Crossover Period 1Arm 1: IGIV, 10% Then Placebo- Crossover Period 2Arm 2: Placebo Then IGIV, 10% - Crossover Period 1Arm 2: Placebo Then IGIV, 10% - Crossover Period 2
Mean Relative Change in Grip Strength in the More Affected Hand-16.36 (-30.92 to -1.80)-30.52 (-43.68 to -17.36)-30.11 (-48.41 to -11.81)23.86 (-23.11 to 70.83)
Statistical analysis
  • Arm 1: IGIV, 10% Then Placebo- Crossover Period 1 vs Arm 1: IGIV, 10% Then Placebo- Crossover Period 2 vs Arm 2: Placebo Then IGIV, 10% - Crossover Period 1 vs Arm 2: Placebo Then IGIV, 10% - Crossover Period 2 · ANOVA · p = 0.005 · Difference in least squared means: 35.13 · 95% CI 8.81 to 61.46Fixed effects ANOVA with factors for sequence (1 or 2), nested within sequence, period (Cross-Over Period 1 or 2), \& treatment (IGIV, 10% or placebo)
SecondaryPercentage of Participants With at Least a 30% Decline in Relative Grip Strength in the More Affected Hand (Measured Using a DynEx Digital Dynamometer)

Relative grip strength change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 30% Decline in Relative Grip Strength in the More Affected Hand (Measured Using a DynEx Digital Dynamometer)
Percentage of participantsDecline Only During IGIV, 10%Decline Only During PlaceboDecline During Both Placebo and IGIV, 10%No Decline During Placebo or IGIV, 10%
Percentage of Participants With at Least a 30% Decline in Relative Grip Strength in the More Affected Hand (Measured Using a DynEx Digital Dynamometer)4.842.94.847.6
Statistical analysis
  • Decline Only During IGIV, 10% vs Decline Only During Placebo vs Decline During Both Placebo and IGIV, 10% vs No Decline During Placebo or IGIV, 10% · McNemar · p = <0.001
SecondaryGrip Strength in the Less Affected Hand

The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. Each grip strength test consisted of 3 maximal repeated contractions (trials). Each participant will perform 2 sessions of grip strength testing. After a 10-minute break, the testing session will be repeated for a total of 6 grip repetitions per hand.

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · kilograms
Grip Strength in the Less Affected Hand
kilogramsBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)27.98 (22.35 to 36.35)29.52 (23.28 to 36.98)29.79 (20.48 to 37.88)29.17 (21.68 to 37.70)26.58 (13.67 to 32.83)28.97 (15.95 to 34.38)29.68 (14.72 to 34.35)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)27.23 (18.73 to 34.45)28.23 (19.72 to 36.80)20.28 (9.61 to 33.44)26.92 (17.52 to 37.72)27.35 (21.58 to 37.12)25.72 (20.18 to 36.55)24.98 (16.02 to 35.85)
SecondaryMean Relative Change in Grip Strength in the Less Affected Hand

Relative Change is defined as 100 \* (End of the Cross-Over Period - Baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Mean · Percent change in grip strength
Mean Relative Change in Grip Strength in the Less Affected Hand
Percent change in grip strengthArm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2
Mean Relative Change in Grip Strength in the Less Affected Hand-2.52 (-7.90 to 2.85)-17.96 (-29.81 to -6.10)-29.22 (-40.62 to -17.83)19.67 (-10.84 to 50.17)
Statistical analysis
  • Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 vs Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 vs Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 vs Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 · ANOVA · p = <0.001 · Difference in least squared means: 32.54 · 95% CI 14.01 to 51.06
SecondaryProportion of Participants That Were Accelerated Forward Into the Next Stabilization Phase (ie Switched to Open-Label IGIV, 10%)

Participants were permitted to switch from blinded treatment with placebo or IGIV, 10% to open label IGIV, 10% if they and investigator agreed that deterioration had occurred to the extent that the participant had unacceptable difficulty carrying out daily activities involving the affected muscles, or decline in grip strength of ≥50% in the more affected hand had occurred.

Time frame:
During the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · Proportion of participants
Proportion of Participants That Were Accelerated Forward Into the Next Stabilization Phase (ie Switched to Open-Label IGIV, 10%)
Proportion of participantsAccelerated Switch During IGIV, 10% and PlaceboAccelerated Switch During Placebo, But Not IGIV, 10%Accelerated Switch During IGIV, 10%, But Not PlaceboNo Accelerated Switch During IGIV, 10% or Placebo
Proportion of Participants That Were Accelerated Forward Into the Next Stabilization Phase (ie Switched to Open-Label IGIV, 10%)0.069.02.428.6
Statistical analysis
  • Accelerated Switch During IGIV, 10% and Placebo vs Accelerated Switch During Placebo, But Not IGIV, 10% vs Accelerated Switch During IGIV, 10%, But Not Placebo vs No Accelerated Switch During IGIV, 10% or Placebo · McNemar · p = <0.001
SecondaryPatient Global Impression of Change

Patient Global Impression of Change was measured on an ordinal scale of 1-7, higher scores representing greater perceived deterioration since the previous efficacy assessment (ranging from (1) very much improved to very much worse (7)). 1. Very much improved 2. Much improved 3. Minimally improved 4. No change 5. Minimally worse 6. Much worse 7. Very much worse

Time frame:
Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Scores on a scale
Patient Global Impression of Change
Scores on a scaleEnd of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV, 10% then Placebo (N= 22, 22, 22, 21, 17, 21)4.0 (3.0 to 4.0)4.0 (4.0 to 4.0)4.0 (4.0 to 4.0)5.0 (5.0 to 6.0)2.0 (2.0 to 4.0)4.0 (3.0 to 4.0)
Placebo then IGIV, 10% (N= 22, 20, 21, 21, 19, 22)4.0 (3.0 to 4.0)6.0 (5.0 to 6.0)3.0 (2.0 to 3.0)4.0 (3.0 to 4.0)4.0 (4.0 to 4.0)4.0 (4.0 to 4.0)
SecondaryOverall Disability Sum Score

The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability).

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Scores on a scale
Overall Disability Sum Score
Scores on a scaleBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)3 (2 to 4)2 (2 to 4)3 (2 to 4)2 (2 to 4)3 (2 to 4)2 (2 to 4)2 (2 to 4)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)3 (2 to 4)3 (2 to 4)4 (3 to 5)3 (2 to 4)3 (2 to 4)4 (2 to 4)3 (2 to 4)
SecondaryOverall Disability Sum Score - Standardized

The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability. Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); Overall Range: 0 (no signs of disability) to 12 (maximum disability). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Scores on a scale
Overall Disability Sum Score - Standardized
Scores on a scaleBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)75.0 (66.7 to 83.3)83.3 (66.7 to 83.3)79.2 (66.7 to 83.3)83.3 (66.7 to 83.3)75.0 (66.7 to 83.3)83.3 (66.7 to 83.3)83.3 (66.7 to 83.3)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)75.0 (66.7 to 83.3)75.0 (66.7 to 83.3)66.7 (58.3 to 75.0)75.0 (66.7 to 83.3)75.0 (66.7 to 83.3)66.7 (66.7 to 83.3)75.0 (66.7 to 83.3)
SecondaryMean Relative Change in Overall Disability Sum Score

Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The overall disability sum scale (based on Merkies et al., 2002) is a patient questionnaire that measures disability (from 0, "no signs of disability" to 12, "most severe disability"). This was standardized to a scale of 0 to 100 (the best score being 100) to allow calculation of relative changes.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Mean · percent change in score
Mean Relative Change in Overall Disability Sum Score
percent change in scoreArm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2
Mean Relative Change in Overall Disability Sum Score-3.14 (-6.55 to 0.27)-5.77 (-10.33 to -1.20)-8.46 (-12.81 to -4.11)0.92 (-2.88 to 4.73)
Statistical analysis
  • Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 vs Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 vs Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 vs Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 · ANOVA · p = 0.002 · Difference in least squared means: 6.03 · 95% CI 2.14 to 9.92
SecondaryTime Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand

The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Seconds
Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand
SecondsBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)20.75 (19.50 to 27.50)22.00 (19.50 to 29.00)20.25 (18.00 to 29.00)21.00 (18.00 to 24.50)20.50 (18.50 to 27.50)20.50 (19.00 to 24.50)20.00 (19.00 to 25.50)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)26.75 (20.50 to 39.00)25.25 (19.00 to 33.50)27.75 (23.00 to 43.50)24.50 (19.00 to 34.50)25.00 (20.00 to 30.50)27.50 (20.50 to 35.50)26.25 (19.50 to 33.00)
SecondaryMean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand

Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Mean · Percent change in time
Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand
Percent change in timeArm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2
Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Dominant Hand-2.57 (-9.99 to 4.86)3.90 (-4.59 to 12.39)29.89 (12.46 to 47.31)4.89 (-9.45 to 19.23)
Statistical analysis
  • Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 vs Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 vs Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 vs Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 · ANOVA · p = <0.001 · Difference in least squared means: -15.57 · 95% CI -24.37 to -6.77
SecondaryTime Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand

The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Seconds
Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand
SecondsBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)25.75 (20.00 to 29.50)22.50 (19.50 to 27.00)24.00 (19.50 to 28.50)23.50 (19.50 to 27.00)25.25 (22.50 to 29.50)21.00 (19.50 to 24.50)23.00 (20.50 to 26.50)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)31.25 (22.50 to 51.00)28.00 (22.50 to 40.00)37.25 (26.25 to 82.75)31.50 (24.00 to 38.50)32.50 (22.00 to 41.00)30.00 (22.50 to 39.50)30.00 (21.00 to 38.50)
SecondaryMean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand

Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The 9-HPT is a quantitative measure of upper extremity (arm and hand) function. Participants picked up the pegs one at a time (nine in total), and put them into the holes on the board as quickly as possible, in any order until all the holes were filled. Then, without pausing, participants removed the pegs one at a time and returned them to the container as quickly as possible. Each participant did this two times with their non-dominant hand. The 9-HCT objective is to see how fast participants could put all of the pegs in and take them out again.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Mean · Percent change in time
Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand
Percent change in timeArm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2
Mean Relative Change in Time Required by Participants to Complete the 9 Hole Peg Board Test (9-HPT) With the Non-Dominant Hand4.78 (-1.65 to 11.21)13.06 (4.46 to 21.65)52.93 (26.82 to 79.05)8.56 (-4.88 to 22.01)
Statistical analysis
  • Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 vs Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 vs Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 vs Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 · ANOVA · p = <0.001 · Difference in least squared means: -26.11 · 95% CI -38.96 to -13.26
SecondaryParticipants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)

The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Scores on a scale
Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)
Scores on a scaleBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)4.80 (2.90 to 6.30)2.95 (1.60 to 5.10)4.10 (2.00 to 5.60)3.50 (1.70 to 5.10)6.85 (5.90 to 8.10)4.50 (2.60 to 5.10)3.70 (1.90 to 5.40)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)4.95 (2.30 to 7.60)3.15 (2.70 to 5.50)7.15 (6.75 to 7.60)5.10 (2.30 to 6.10)4.60 (2.40 to 5.90)4.50 (2.60 to 6.00)5.15 (2.80 to 6.30)
SecondaryMean Relative Change in Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)

Relative Change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The VAS measured patients' assessment of physical functioning on a 10 centimeter scale of 0-10, on which 0 represents "no symptoms" and 10 "disabled, unable to use affected limbs".

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Mean · Percent change in assessment
Mean Relative Change in Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)
Percent change in assessmentArm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2
Mean Relative Change in Participants' Assessment of Physical Functioning on a Visual Analog Scale (VAS)140.92 (-1.35 to 283.19)321.75 (-73.45 to 716.95)258.09 (-100.83 to 617.01)5.75 (-11.54 to 23.04)
Statistical analysis
  • Arm 1: IGIV, 10% Then Placebo- IGIV, 10% Cross-over Period 1 vs Arm 1: IGIV, 10% Then Placebo- Placebo Cross-over Period 2 vs Arm 2: Placebo Then IGIV, 10%- Placebo Cross-over Period 1 vs Arm 2: Placebo Then IGIV, 10%- IGIV, 10% Cross-over Period 2 · ANOVA · p = 0.059 · Difference in least squared means: -216.60 · 95% CI -490.41 to 57.22
PrimaryCo-Primary Endpoint: Guy's Neurologic Disability Scale (GNDS) for Upper Limbs

GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.

Time frame:
Week 0, then at Last infusion cycle for each study part (Day 8 of last treatment cycle for 2-week interval or Day 15 of last treatment cycle for 3 or 4 -week interval), then at the end of study visit
Reported as:
Median · Scores on a scale
Co-Primary Endpoint: Guy's Neurologic Disability Scale (GNDS) for Upper Limbs
Scores on a scaleBefore Stabilization 1End of Stabilization 1End of Cross-Over 1End of Stabilization 2End of Cross-Over 2End of Stabilization 3End of the Study
IGIV then Placebo (N= 22, 22, 22, 22, 22, 17, 21)2.0 (2.0 to 3.0)2.0 (2.0 to 2.0)2.0 (2.0 to 2.0)2.0 (2.0 to 3.0)2.5 (2.0 to 3.0)2.0 (2.0 to 2.0)2.0 (2.0 to 2.0)
Placebo then IGIV (N= 22, 22, 20, 21, 21, 19, 22)2.0 (2.0 to 3.0)2.0 (2.0 to 3.0)2.0 (2.0 to 3.0)2.0 (1.0 to 3.0)2.0 (2.0 to 3.0)2.0 (2.0 to 3.0)2.0 (2.0 to 3.0)
Post-hocProportion of Participants With at Least a 30% Decline in Relative Grip Strength in the Less Affected Hand (Measured Using a DynEx Digital Dynamometer)

Relative grip strength change is defined as 100 \* (End of the Cross-Over Period - baseline of Cross-Over Period) divided by baseline of Cross-Over Period. The grip strength was measured using a DynEx digital dynamometer. The result of grip strength was recorded to a resolution of 0.1 kg. For statistical analysis, the mean of (usually three) trials for cross-over sessions 1 and 2 was computed and the mean of the sessions was used in the analysis as the result of the grip strength measurement. Only if no grip strength testing could be performed the results were considered as missing.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Number · Proportion of participants
Proportion of Participants With at Least a 30% Decline in Relative Grip Strength in the Less Affected Hand (Measured Using a DynEx Digital Dynamometer)
Proportion of participantsDecline Only During IGIV, 10%Decline Only During PlaceboDecline During Both Placebo and IGIV, 10%No Decline During Placebo and IGIV, 10%
Proportion of Participants With at Least a 30% Decline in Relative Grip Strength in the Less Affected Hand (Measured Using a DynEx Digital Dynamometer)0.031.02.466.7
Statistical analysis
  • Decline Only During IGIV, 10% vs Decline Only During Placebo vs Decline During Both Placebo and IGIV, 10% vs No Decline During Placebo and IGIV, 10% · McNemar · p = <0.001
PrimaryCo-Primary Endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS)

GNDS (based on Sharrack and Hughes, 1999) for the upper limbs were integers 0 to 5, with 0 indicating no impairment.

Time frame:
Baseline and last infusion cycle during the two study cross-over periods, approximately weeks 13 and 24; and weeks 37 and 48 (i.e. baseline and end of Study Parts 2 and 4)
Reported as:
Number · Proportion of participants
Co-Primary Endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS)
Proportion of participantsDeterioration After IGIV, 10% and PlaceboDeterioration After Placebo, But Not IGIV, 10%Deterioration After IGIV, 10%, But Not PlaceboNo Deterioration After IGIV, 10% or Placebo
Co-Primary Endpoint: Proportion of Participants With Deterioration in Guy's Neurological Disability Score (GNDS)4.8 (2.0 to 2.0)35.7 (2.0 to 3.0)11.9 (2.0 to 3.0)47.6 (2.0 to 3.0)
Statistical analysis
  • Deterioration After IGIV, 10% and Placebo vs Deterioration After Placebo, But Not IGIV, 10% vs Deterioration After IGIV, 10%, But Not Placebo vs No Deterioration After IGIV, 10% or Placebo · McNemar · p = 0.021
PrimaryRate of Temporally Associated Adverse Events (AEs) Per Infusion

The total number of all AEs which begin during or within 72 hours of completion of an infusion, irrespective of being related or not related to the study product (IGIV, 10% or Placebo), divided by the total number of infusions, and multiplied by 100.

Time frame:
Within 72 hours of completion of an infusion during the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · Percentage of AEs per infusion
Rate of Temporally Associated Adverse Events (AEs) Per Infusion
Percentage of AEs per infusionArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
Rate of Temporally Associated Adverse Events (AEs) Per Infusion11.513.224.611.6
PrimaryThe Percentage of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason
Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · percentage of participants
The Percentage of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason
percentage of participantsArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
The Percentage of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason9.10.04.84.8
PrimaryThe Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason
Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · percentage of infusions
The Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason
percentage of infusionsArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
The Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Any Reason2.90.01.60.7
SecondaryRate of Related AEs Per Infusion

The total number of AEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.

Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · AEs per infusion
Rate of Related AEs Per Infusion
AEs per infusionArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
Rate of Related AEs Per Infusion4.820.644.315.9
SecondaryRate of Related SAEs Per Infusion

The total number of SAEs determined by the investigator to be related to the study product that occur at any time during the study divided by the total number of infusions, and multiplied by 100.

Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · SAEs per infusion
Rate of Related SAEs Per Infusion
SAEs per infusionArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
Rate of Related SAEs Per Infusion0.00.00.00.7
SecondaryThe Proportion of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs
Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · proportion of participants
The Proportion of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs
proportion of participantsArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
The Proportion of Participants for Whom the Infusion Rate of Any Infusion Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs0.00.00.04.8
SecondaryThe Proportion of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs
Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · proportion of infusions
The Proportion of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs
proportion of infusionsArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
The Proportion of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped for Tolerability Concerns/AEs0.00.00.00.7
SecondaryThe Proportion of Infusions Associated With One or More AEs Related to the Study Product
Time frame:
Throughout the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · proportion of infusions
The Proportion of Infusions Associated With One or More AEs Related to the Study Product
proportion of infusionsArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
The Proportion of Infusions Associated With One or More AEs Related to the Study Product3.819.134.413.0
PrimaryThe Percentage of Participants Reporting One or More Moderate or Severe AEs That Began During Infusion or Within 72 Hours of Completion of an Infusion
Time frame:
Within 72 hours of completion of an infusion during the two study cross-over periods, approximately weeks 13-24 and weeks 37-48 (i.e. Study Parts 2 and 4)
Reported as:
Number · percentage of participants
The Percentage of Participants Reporting One or More Moderate or Severe AEs That Began During Infusion or Within 72 Hours of Completion of an Infusion
percentage of participantsArm 1: IGIV, 10% Then Placebo- IGIV, 10% PeriodArm 1: IGIV, 10% Then Placebo- Placebo PeriodArm 2: Placebo Then IGIV, 10%- Placebo PeriodArm 2: Placebo Then IGIV, 10%- IGIV, 10% Period
The Percentage of Participants Reporting One or More Moderate or Severe AEs That Began During Infusion or Within 72 Hours of Completion of an Infusion4.527.319.04.8

Adverse events

Collected over Throughout the study period, approximately three years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV, 10%—2/44 (4.5%)35/44 (79.5%)
Placebo—0/43 (0%)33/43 (76.7%)
Most frequent serious events
Most frequent serious events
EventIGIV, 10%Placebo
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/440/43
Vision blurredEye disorders1/440/43
Most frequent other events
Showing 10 of 22
Most frequent other events
EventIGIV, 10%Placebo
NEUROLOGICAL DECOMPENSATIONNervous system disorders10/4425/43
HEADACHENervous system disorders16/442/43
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations9/440/43
MUSCLE SPASMSMusculoskeletal and connective tissue disorders8/442/43
INFLUENZA LIKE ILLNESSGeneral disorders7/441/43
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders7/440/43
MUSCULAR WEAKNESSMusculoskeletal and connective tissue disorders6/442/43
BACK PAINMusculoskeletal and connective tissue disorders5/441/43
CONTUSIONInjury, poisoning and procedural complications5/442/43
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders4/443/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Study Participants
Mean51.64 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female12
Male32
08

Study locations

17 sites
  • Los Angeles, California, United States
  • Stanford, California, United States
  • Centennial, Colorado, United States
  • Miami, Florida, United States
  • Kansas City, Kansas, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Saint Louis, Missouri, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Houston, Texas, United States
  • Seattle, Washington, United States
  • Calgary, Alberta, Canada
  • Kingston, Ontario, Canada
  • London, Ontario, Canada
  • Montreal, Quebec, Canada
  • Aarhus, Denmark
09

References and documents

Publications

  • Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA; Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry. 2002 May;72(5):596-601. doi: 10.1136/jnnp.72.5.596. PubMed 11971045 ↗
  • Sharrack B, Hughes RA. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler. 1999 Aug;5(4):223-33. doi: 10.1177/135245859900500406. PubMed 10467380 ↗
  • Koski CL, Schiff RI, Oh M, Lee D. Characteristics of patients with multifocal motor neuropathy enrolled in a randomized controlled trial of intravenous gammaglobulin. Poster. 63rd Annual Meeting of American Academy of Neurology (AAN), April 9-16, 2011, Honolulu, HI, USA.
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2008 to primary completion in Aug 2011, 35 months.

Results were first posted in Mar 2013, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 24, 2008
StartActual
Aug 22, 2008
Primary completionActual
Aug 11, 2011
CompletionActual
Aug 11, 2011
Results first posted
Mar 13, 2013
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00666263
Responsible party
Sponsor
First posted
Apr 24, 2008
Start date
Aug 22, 2008
Primary completion
Aug 11, 2011
Completion
Aug 11, 2011
Results posted
Mar 13, 2013
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion